RIPK1 and rheumatoid arthritis: Other RIPK1 inhibitors have been developed by GlaxoSmithKline, among which GSK2982772 is currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis [137,138] and GSK3145095 has terminated the phase I clinical trials for solid tumors [8].